Search
for

    Sort by

    Community Join

    60-90 / 1000+ results

      community AH-001 another topical AR degrader beside GT20029, completed Phase I

       8 upvotes 10 months ago
      AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

      community when is kintor going to start phase 3 for gt20029?

       6 upvotes 2 years ago
      The conversation is about the timeline for Kintor's phase 3 trials for GT20029 and the potential release of the product in three years. It also mentions treatments like Minoxidil, finasteride, and RU58841.

      community Anyone hear of Ursolic Acid?

       3 upvotes 7 years ago
      Ursolic acid, found in apple peels, lemongrass, rosemary, and lavender, may have anti-androgen effects similar to finasteride. It might be beneficial for hair health when used with other treatments like Minoxidil, Finasteride, and RU58841.

      community Peter h diamandis Dr David Sinclair podcast

      6 months ago
      Hair loss treatments discussed include Minoxidil, finasteride, and RU58841. There is skepticism about claims of a breakthrough, despite FDA approval for human trials.

      community Clascoterone full results 2026

       7 upvotes 2 weeks ago
      Clascoterone results are anticipated to be released in fall 2026, possibly at the EADV conference. Users express skepticism and humor about the release date.

      community RU58841 legit source from europe and china

      in Product  1 upvotes 2 years ago
      A user is seeking advice on purchasing RU58841 from Biolab Shop in Poland and is looking for trustworthy sources that deliver to Germany from Europe or China. They are interested in the product's composition and user experiences.

      community Cosmo Pharma Lists Breezula Phase 3 Trial on ClinicalTrials.gov

       25 upvotes 3 years ago
      A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.

      community Be careful ordering from Umbrella Labs.

       30 upvotes 10 months ago
      A user experienced issues with an order from Umbrella Labs, initially not receiving their product, PP405, and facing poor customer service, but eventually received the order after posting about it. Other users also reported similar problems with incomplete orders and lack of communication from the company.

      community Clascoterone full results in July

       14 upvotes 4 months ago
      Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.

      community Clascoterone - clearnet vendor

      in Chat  2 upvotes 8 months ago
      The conversation is about finding a clearnet vendor for clascoterone, also known as Winlevi, for hair loss treatment. The user is seeking recommendations via direct message.

      community DIY Cetirizin topical 1% with micro needling

       2 upvotes 8 months ago
      The conversation is about using a DIY topical Cetirizine 1% solution with microneedling for hair loss treatment. Concerns were raised about potential side effects and the effectiveness of Cetirizine for this purpose.

      community Oxytocin Pathway and Cinnamic Acid Research

       14 upvotes 2 years ago
      The conversation discusses the potential of cinnamic acid for hair growth. It also mentions treatments like Minoxidil, finasteride, and RU58841.

      community SUBE3 for sale in the gray market?

       5 upvotes 1 year ago
      SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

      community Kintor going after Pelage? KT-215

       9 upvotes 2 weeks ago
      Kintor is potentially pursuing a new hair loss treatment, KT-215, while users express skepticism about the speed and reliability of new product releases. There is a general sentiment that Chinese companies might be more promising in delivering timely solutions.

      community No access to RU, Pyri. Any alternative anti androgen?

      in Treatment  4 upvotes 1 year ago
      The conversation discusses alternatives to RU58841 for hair loss treatment, with suggestions including topical spironolactone, peppermint and rosemary oils, and saw palmetto. The user also considers ordering RU58841 from China but finds it too expensive.

      community A scary individual report of RU58841.

       33 upvotes 1 year ago
      RU58841 caused severe side effects like heart palpitations and shortness of breath, leading the user to stop using it. Minoxidil and finasteride were effective without side effects, while RU58841's safety and effectiveness remain uncertain.

      community Let's talk about Tsuji and Shiseido

       4 upvotes 8 years ago
      The conversation discusses hair loss treatments, focusing on Tsuji's hair cloning and Shiseido's RCH-01, with skepticism about their effectiveness on humans. It compares these to PRP, noting PRP's higher efficacy in studies.

      community What is the best legit source of RU58841 in the UK?

      in Product  6 upvotes 2 years ago
      A user is seeking a trusted supplier for RU58841 in the UK, expressing doubts about their current source, rudirect, and considering Anagenic and receptorchem. They are asking for recommendations for other suppliers.

      community Anyone here ever used KY-19382 or another indirubin analogue?

       2 upvotes 1 year ago
      KY-19382, an indirubin derivative, is discussed for its potential to stimulate hair growth and create new hair follicles. The conversation seeks experiences with synthesizing, topically applying, or orally administering KY-19382.